{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T14:20:36Z","timestamp":1783088436122,"version":"3.54.6"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,5,3]],"date-time":"2027-05-03T00:00:00Z","timestamp":1809302400000},"content-version":"am","delay-in-days":306,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Government of Japan Ministry of Health Labour and Welfare","doi-asserted-by":"publisher","award":["23AA2003"],"award-info":[{"award-number":["23AA2003"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Government of Japan Ministry of Health Labour and Welfare","doi-asserted-by":"publisher","award":["24AA2006"],"award-info":[{"award-number":["24AA2006"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.lungcan.2026.109429","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:33:14Z","timestamp":1777501994000},"page":"109429","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Protective effect of bevacizumab against interstitial lung disease in non-squamous non-small-cell lung cancer: a nationwide target trial emulation study"],"prefix":"10.1016","volume":"217","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8260-4200","authenticated-orcid":false,"given":"Chikako","family":"Iwai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0004-4743","authenticated-orcid":false,"given":"Hiroki","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1894-0290","authenticated-orcid":false,"given":"Kiyohide","family":"Fushimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Yasunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2026.109429_b0005","doi-asserted-by":"crossref","unstructured":"G.J. Riely, D.E. Wood, D.S. Ettinger, D.L. Aisner, W. Akerley, J.R. Bauman, A. Bharat, D.S. Bruno, J.Y. Chang, L.R. Chirieac, M. DeCamp, A.P. Desai, T.J. Dilling, J. Dowell, G.A. Durm, S. Gettinger, T.E. Grotz, M.A. Gubens, A. Juloori, R.P. Lackner, M. Lanuti, J. Lin, B.W. Loo, C.M. Lovly, F. Maldonado, E. Massarelli, D. Morgensztern, T.C. Mullikin, T. Ng, D. Owen, D.H. Owen, S.P. Patel, T. Patil, P.M. Polanco, J. Riess, T.A. Shapiro, A.P. Singh, J. Stevenson, A. Tam, T. Tanvetyanon, J. Yanagawa, S.C. Yang, E. Yau, K.M. Gregory, L. Hang, Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology, J Natl Compr Canc Netw 22 (2024) 249\u2013274. https:\/\/doi.org\/10.6004\/jnccn.2204.0023.","DOI":"10.6004\/jnccn.2204.0023"},{"key":"10.1016\/j.lungcan.2026.109429_b0010","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.3390\/cancers16162837","article-title":"Lung cancer and interstitial lung diseases","volume":"16","author":"Drakopanagiotakis","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.lungcan.2026.109429_b0015","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/pmic.201500171","article-title":"A proteomics approach to identifying key protein targets involved in VEGF inhibitor mediated attenuation of bleomycin-induced pulmonary fibrosis","volume":"16","author":"Kulkarni","year":"2016","journal-title":"Proteomics"},{"key":"10.1016\/j.lungcan.2026.109429_b0020","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/jcp.25608","article-title":"MnTBAP inhibits bleomycin-induced pulmonary fibrosis by regulating VEGF and Wnt signaling","author":"Venkatadri","year":"2017","journal-title":"J Cell Physiol 232"},{"key":"10.1016\/j.lungcan.2026.109429_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103703","article-title":"Association between bevacizumab with cancer drug therapies and drug-induced interstitial lung disease in patients with solid tumor: a systematic review and meta-analysis of randomized clinical trials","volume":"174","author":"Nozawa","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.lungcan.2026.109429_b0030","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12890-019-0838-2","article-title":"Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer","volume":"19","author":"Hamada","year":"2019","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.lungcan.2026.109429_b0035","doi-asserted-by":"crossref","first-page":"106","DOI":"10.37737\/ace.24015","article-title":"Updated information on the diagnosis procedure combination data","volume":"6","author":"Yasunaga","year":"2024","journal-title":"Ann. Clin. Epidemiol."},{"key":"10.1016\/j.lungcan.2026.109429_b0040","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.je.2016.09.009","article-title":"Validity of diagnoses, procedures, and laboratory data in Japanese administrative data","volume":"27","author":"Yamana","year":"2017","journal-title":"J. Epidemiol."},{"key":"10.1016\/j.lungcan.2026.109429_b0045","doi-asserted-by":"crossref","first-page":"76","DOI":"10.37737\/ace.1.3_76","article-title":"Real World data in Japan: chapter II the diagnosis procedure combination database","volume":"1","author":"Yasunaga","year":"2019","journal-title":"Ann. Clin. Epidemiol."},{"key":"10.1016\/j.lungcan.2026.109429_b0050","doi-asserted-by":"crossref","first-page":"20","DOI":"10.37737\/ace.22004","article-title":"Validation study of algorithms to identify malignant tumors and serious infections in a japanese administrative healthcare database","volume":"4","author":"Nishikawa","year":"2022","journal-title":"Ann. Clin. Epidemiol."},{"key":"10.1016\/j.lungcan.2026.109429_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2021.102016","article-title":"Validity of initial cancer diagnoses in the diagnosis procedure combination data in Japan","volume":"74","author":"Shigemi","year":"2021","journal-title":"Cancer Epidemiol."},{"key":"10.1016\/j.lungcan.2026.109429_b0060","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1001\/jama.2022.21383","article-title":"Target trial emulation: a framework for causal inference from observational data","volume":"328","author":"Hern\u00e1n","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.lungcan.2026.109429_b0065","article-title":"Target trial emulation: applying principles of randomised trials to observational studies","volume":"378","author":"Matthews","year":"2022","journal-title":"BMJ"},{"issue":"Suppl 2","key":"10.1016\/j.lungcan.2026.109429_b0070","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1038\/sj.bjc.6602064","article-title":"Diagnosis and management of drug-associated interstitial lung disease","volume":"91","author":"M\u00fcller","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2026.109429_b0075","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3390\/jcm7100356","article-title":"Drug-induced Interstitial lung disease: a systematic review","volume":"7","author":"Skeoch","year":"2018","journal-title":"J Clin Med"},{"key":"10.1016\/j.lungcan.2026.109429_b0080","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1136\/thoraxjnl-2020-215824","article-title":"Risk of drug-induced interstitial lung disease in hospitalised patients: a nested case-control study","volume":"76","author":"Jo","year":"2021","journal-title":"Thorax"},{"key":"10.1016\/j.lungcan.2026.109429_b0085","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s40261-024-01400-z","article-title":"Diagnosis and management of drug-induced interstitial lung disease in the context of anti-cancer therapy: a multidisciplinary viewpoint by portuguese experts","volume":"44","author":"Fontes e Sousa","year":"2024","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.lungcan.2026.109429_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100404","article-title":"Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment","volume":"7","author":"Conte","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.lungcan.2026.109429_b0095","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/CM9.0000000000003149","article-title":"Cancer therapy-related interstitial lung disease","volume":"138","author":"Zhou","year":"2025","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.lungcan.2026.109429_b0100","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1200\/JCO.20.01296","article-title":"Antiemetics: ASCO guideline update","volume":"38","author":"Hesketh","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2026.109429_b0105","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jpainsymman.2024.01.037","article-title":"PASQol Study Group, A Randomized Controlled Trial of Betamethasone on Fatigue in Patients With Advanced Cancer","volume":"67","author":"Miyazaki","year":"2024","journal-title":"J. Pain Sympt. Manage."},{"key":"10.1016\/j.lungcan.2026.109429_b0110","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"National comprehensive cancer network, management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2026.109429_b0115","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1164\/rccm.201604-0801CI","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report","volume":"194","author":"Collard","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"10.1016\/j.lungcan.2026.109429_b0120","article-title":"Treatments and outcomes of adult parapharyngeal and retropharyngeal abscess: 1882 cases from a Japanese nationwide database","volume":"44","author":"Konishi","year":"2022","journal-title":"Am. J. Otolaryngol."},{"key":"10.1016\/j.lungcan.2026.109429_b0125","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1253\/circj.CJ-21-0584","article-title":"Barthel index score predicts mortality in elderly heart failure \u2013 a goal of comprehensive cardiac rehabilitation","volume":"86","author":"Katano","year":"2022","journal-title":"Circ. J."},{"key":"10.1016\/j.lungcan.2026.109429_b0130","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12904-022-01017-z","article-title":"Barthel Index is a valid and reliable tool to measure the functional independence of cancer patients in palliative care","volume":"21","author":"Dos Santos Barros","year":"2022","journal-title":"BMC Palliat Care"},{"key":"10.1016\/j.lungcan.2026.109429_b0135","doi-asserted-by":"crossref","unstructured":"C. Hern\u00e1ndez-Quiles, M. Bernabeu-Wittel, L.M. P\u00e9rez-Belmonte, P. Mac\u00edas-Mir, D. Camacho-Gonz\u00e1lez, B. Massa, M. Maiz-Jim\u00e9nez, M. Ollero-Baturone, PALIAR investigators, Concordance of Barthel Index, ECOG-PS, and Palliative Performance Scale in the assessment of functional status in patients with advanced medical diseases, BMJ Support Palliat Care 7 (2017) 300\u2013307. https:\/\/doi.org\/10.1136\/bmjspcare-2015-001073.","DOI":"10.1136\/bmjspcare-2015-001073"},{"key":"10.1016\/j.lungcan.2026.109429_b0140","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chron. Dis."},{"key":"10.1016\/j.lungcan.2026.109429_b0145","article-title":"Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners","volume":"367","author":"Desai","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.lungcan.2026.109429_b0150","doi-asserted-by":"crossref","unstructured":"N. Mehta, A. Kalra, A.S. Nowacki, S. Anjewierden, Z. Han, P. Bhat, A.E. Carmona-Rubio, M. Jacob, G.W. Procop, S. Harrington, A. Milinovich, L.G. Svensson, L. Jehi, J.B. Young, M.K. Chung, Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19), JAMA Cardiol 5 (2020) 1020\u20131026. https:\/\/doi.org\/10.1001\/jamacardio.2020.1855.","DOI":"10.1001\/jamacardio.2020.1855"},{"key":"10.1016\/j.lungcan.2026.109429_b0155","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1080\/01621459.2016.1260466","article-title":"Balancing covariates via propensity score weighting","volume":"113","author":"Li","year":"2018","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.lungcan.2026.109429_b0160","first-page":"250","article-title":"Addressing extreme propensity scores via the overlap weights","volume":"188","author":"Li","year":"2019","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.lungcan.2026.109429_b0165","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat. Med."},{"key":"10.1016\/j.lungcan.2026.109429_b0170","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1093\/ndt\/gft355","article-title":"When do we need competing risks methods for survival analysis in nephrology?","volume":"28","author":"Noordzij","year":"2013","journal-title":"Nephrol. Dial Transplant"},{"key":"10.1016\/j.lungcan.2026.109429_b0175","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","article-title":"Introduction to the analysis of survival data in the presence of competing risks","volume":"133","author":"Austin","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.lungcan.2026.109429_b0180","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.h2622","article-title":"Statistics notes: bootstrap resampling methods","volume":"350","author":"Bland","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.lungcan.2026.109429_b0185","doi-asserted-by":"crossref","first-page":"101","DOI":"10.37737\/ace.22013","article-title":"Theory and practice of propensity score analysis","volume":"4","author":"Hashimoto","year":"2022","journal-title":"Ann. Clin. Epidemiol."},{"key":"10.1016\/j.lungcan.2026.109429_b0190","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/sim.5984","article-title":"The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments","volume":"33","author":"Austin","year":"2014","journal-title":"Statist. Med."},{"key":"10.1016\/j.lungcan.2026.109429_b0195","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the e-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.lungcan.2026.109429_b0200","article-title":"A real-world study on the effectiveness and safety of pembrolizumab plus chemotherapy for nonsquamous NSCLC","volume":"3","author":"Fujimoto","year":"2022","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.lungcan.2026.109429_b0205","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.lungcan.2021.08.015","article-title":"Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer","volume":"161","author":"Morimoto","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109429_b0210","doi-asserted-by":"crossref","first-page":"R130","DOI":"10.1186\/cc5042","article-title":"The early responses of VEGF and its receptors during acute lung injury: implication of VEGF in alveolar epithelial cell survival","volume":"10","author":"Mura","year":"2006","journal-title":"Crit Care"},{"key":"10.1016\/j.lungcan.2026.109429_b0215","doi-asserted-by":"crossref","first-page":"92192","DOI":"10.1172\/jci.insight.92192","article-title":"Antifibrotic role of vascular endothelial growth factor in pulmonary fibrosis","volume":"e92192","author":"Murray","year":"2017","journal-title":"JCI Insight 2"},{"issue":"2000","key":"10.1016\/j.lungcan.2026.109429_b0220","first-page":"1474","article-title":"HIF-1: mediator of physiological and pathophysiological responses to hypoxia","volume":"88","author":"Semenza","year":"1985","journal-title":"J. Appl. Physiol"},{"key":"10.1016\/j.lungcan.2026.109429_b0225","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1136\/thx.2005.040204","article-title":"Vascular endothelial growth factor (VEGF) in acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): paradox or paradigm?","volume":"61","author":"Medford","year":"2006","journal-title":"Thorax"},{"key":"10.1016\/j.lungcan.2026.109429_b0230","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1164\/rccm.201603-0568OC","article-title":"Differential expression of VEGF-Axxx isoforms is critical for development of pulmonary fibrosis","volume":"196","author":"Barratt","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.lungcan.2026.109429_b0235","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.3390\/ijms19051269","article-title":"VEGF (vascular endothelial growth factor) and fibrotic lung disease","volume":"19","author":"Barratt","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.lungcan.2026.109429_b0240","doi-asserted-by":"crossref","unstructured":"S. J, L. H, Z. X, H. X, Effects of Vascular Endothelial Growth Factor in Recovery Phase of Acute Lung Injury in Mice, Lung 193 (2015). https:\/\/doi.org\/10.1007\/s00408-015-9803-x.","DOI":"10.1007\/s00408-015-9803-x"},{"key":"10.1016\/j.lungcan.2026.109429_b0245","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.lungcan.2026.109429_b0250","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"INBUILD trial investigators, nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109429_b0255","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109429_b0260","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1007\/s00210-020-01947-6","article-title":"Vascular endothelial growth factor contributes to lung vascular hyperpermeability in sepsis-associated acute lung injury","volume":"393","author":"Tomita","year":"2020","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.lungcan.2026.109429_b0265","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1200\/JCO.2010.32.3220","article-title":"Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies","volume":"29","author":"Hurwitz","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109429_b0270","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.jaccao.2020.06.004","article-title":"Comprehensive characterization of the vascular effects of cisplatin-based chemotherapy in patients with testicular cancer","volume":"2","author":"Cameron","year":"2020","journal-title":"JACC CardioOncol."},{"key":"10.1016\/j.lungcan.2026.109429_b0275","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1200\/JCO.2011.35.5669","article-title":"High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis","volume":"29","author":"Moore","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109429_b0280","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1097\/CAD.0000000000000625","article-title":"Venous thromboembolic events in patients with lung cancer treated with cisplatin-based versus carboplatin\/nedaplatin-based chemotherapy","volume":"29","author":"Mitani","year":"2018","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.lungcan.2026.109429_b0285","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s10147-019-01431-z","article-title":"The Japanese lung cancer society guideline for non-small cell lung cancer, stage IV","volume":"24","author":"Akamatsu","year":"2019","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109429_b0290","unstructured":"Japan Lung Cancer Society, ed. Lung cancer clinical practice guidelines 2024- including malignant pleural mesothelioma and thymic tumors. 8th ed. Tokyo- Kanehara & Co., Ltd.; 2024. ISBN- 978-4-307-20486-6."},{"key":"10.1016\/j.lungcan.2026.109429_b0295","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/jamaoncol.2023.5258","article-title":"Atezolizumab and platinum plus pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung cancer: a phase 3 randomized clinical trial","volume":"10","author":"Shiraishi","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.lungcan.2026.109429_b0300","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.948597","article-title":"A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer","volume":"13","author":"Shao","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lungcan.2026.109429_b0305","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000314980","article-title":"Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis","volume":"79","author":"Hapani","year":"2010","journal-title":"Oncology"},{"key":"10.1016\/j.lungcan.2026.109429_b0310","unstructured":"Ministry of Health, Labour and Welfare (Japan). Vital Statistics of Japan, final data, 2023. Deaths by place of occurrence and year. Vol 1, Table 5-21. e-Stat Statistical Table Display ID: 0003411665. Tokyo: Ministry of Health, Labour and Welfare; 2025."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226004903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226004903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T13:37:29Z","timestamp":1783085849000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226004903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":62,"alternative-id":["S0169500226004903"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109429","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Protective effect of bevacizumab against interstitial lung disease in non-squamous non-small-cell lung cancer: a nationwide target trial emulation study","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109429","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109429"}}